
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
The company opened its new global headquarters in Japan.
Takeda Pharmaceutical announced the opening of its new headquarters in Nihonbashi, Tokyo on July 2, 2018. The building was completed in March 2018.
The company announced that it agreed to sell its previous Tokyo headquarters as well as its Shin-Edobashi building to Takashimaya Company in
Source:






